Approval · Notice of Compliance 16368 · 2014
EYLEA: Notice of Compliance 16368
Issued November 28, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16368
- Date
- November 28, 2014
- Company
- Bayer Inc.Elkhart, Indiana, United States
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: eylea is indicated for the treatment of diabetic macular edema (dme)
- Therapeutic class
- Ohthalmological/antineovascularization agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EYLEA | 02415992 | Marketed |
Medicinal ingredients
- AFLIBERCEPT 40 MG per ML